ENDPOINTS

Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data

Yesterday

News Briefing

ADC Therapeutics reveals layoffs, $100M PIPE; Third Harmonic seeks buyer for asset

2 days ago

News Briefing

Lilly pledges more than $650M to muscle health biotech; Cogent gets $50M

3 days ago

News Briefing

Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issues

4 days ago

News Briefing

Avidity to seek accelerated approval for FSHD drug; Axsome to run another trial

5 days ago

News Briefing

Kelun's $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kids

Last week

News Briefing

Biopharma leaders carving a path for the industry’s LGBTQ+ community

Last week

People

Special

Cullinan's deal for T cell engager from China; Kardigan buys late-stage heart drug

Last week

News Briefing

Vigil drug fails a Phase 2; Merus aims to raise $300M

Last week

News Briefing

Sanofi pays out two STAT6 milestones; Theravance sells more Trelegy royalties

Last week

News Briefing

Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone

3 weeks ago

News Briefing

Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff

3 weeks ago

News Briefing

Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fight

3 weeks ago

News Briefing

ITM reveals up to $262M debt financing; Caris Life Sciences to go public

3 weeks ago

News Briefing

GLP-1s may cut cancer risk; Gyre’s stock falls after hep B data and offering

4 weeks ago

News Briefing

Moderna pulls application for Covid-flu shot; Another IPO in Hong Kong

4 weeks ago

News Briefing

SV Health’s $269M dementia fund; Schrödinger lays off 7% of staff

4 weeks ago

News Briefing

Ionis details late-stage data for heart drug; Armata’s promising staph infection therapy

4 weeks ago

News Briefing

FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval

5 weeks ago

News Briefing

Enliven stops work on solid tumor drug; Pulmatrix to divest assets

5 weeks ago

News Briefing

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

Last month

News Briefing

Axsome's $570M loan with Blackstone; Altimmune makes its own credit deal

Last month

News Briefing

FDA clears in vivo blood stem cell editing trial; Abeona's $155M PRV sale

Last month

News Briefing

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

Last month

News Briefing

about the author

author articles

Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data

ADC Therapeutics reveals layoffs, $100M PIPE; Third Harmonic seeks buyer for asset

Lilly pledges more than $650M to muscle health biotech; Cogent gets $50M

Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issues

Avidity to seek accelerated approval for FSHD drug; Axsome to run another trial

Kelun's $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kids

Biopharma leaders carving a path for the industry’s LGBTQ+ community

Cullinan's deal for T cell engager from China; Kardigan buys late-stage heart drug

Vigil drug fails a Phase 2; Merus aims to raise $300M

Sanofi pays out two STAT6 milestones; Theravance sells more Trelegy royalties

Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone

Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff

Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fight

ITM reveals up to $262M debt financing; Caris Life Sciences to go public

GLP-1s may cut cancer risk; Gyre’s stock falls after hep B data and offering

Moderna pulls application for Covid-flu shot; Another IPO in Hong Kong

SV Health’s $269M dementia fund; Schrödinger lays off 7% of staff

Ionis details late-stage data for heart drug; Armata’s promising staph infection therapy

FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval

Enliven stops work on solid tumor drug; Pulmatrix to divest assets

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

Axsome's $570M loan with Blackstone; Altimmune makes its own credit deal

FDA clears in vivo blood stem cell editing trial; Abeona's $155M PRV sale

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China